News @ Xpedite
July 2021 - New product SwiftX™ DNA launched
Xpedite Diagnostics proudly announces that our new product SwiftX™ DNA is finally launched.
It is designed to enable extraction of bacterial, parasite, virus, animal and human DNA from a broad range of sample types, solid samples, swabs and small volumes of liquids can be directly extracted. Due to the reverse purification mechanism, nucleic acids extracted with SwiftX DNA are performing better than those from other direct lysis products, because potential inhibitors are effectively removed.
To achieve a high sensitivity, SwiftX DNA features a cell concentration step applicable to liquid samples. With that, DNA can be extracted with high efficiency from urine, blood, saliva, cell cultures and others.
May 2021 - Xpedite Diagnostics is now ISO 9001:2015 certified
In late April Xpedite Diagnostics received the initial certification audit for independent certification of its quality management system according to ISO 9001:2015. The certificate was issues in early May. Our certifier QA Technic is recognized by the renowned German Accreditation Body DAkkS.
February 2021 - Launch of CE-IVD version of SwiftX™ Swabs
Xpedite Diagnostics is proud to announce that we have transformed our successful rapid nucleic acid extraction kit SwiftX™ Swabs into a CE-marked device under IVD Directive 98/79/EC.
November 2020 - Foundation of company and launch of first product
Xpedite Diagnostics GmbH was founded in November 2020. We started off immediately with launching our first product - SwiftX™ Swabs.
SwiftX™ Swabs is a simple yet powerful solution for nucleic acid extraction from swabs taken from throat, nose, buccal, skin and the like. It extracts DNA and RNA from viruses as well as host cells. The kit was validated for extraction of SARS-CoV-2 RNA from Covid19 patients. It is a cost-efficient alternative to classical NA extraction devices and is suited for high-throughput applications as well as for use at the point-of-care.